https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53150 Wed 29 May 2024 15:41:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34079 Wed 17 Nov 2021 16:31:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53953 Wed 13 Mar 2024 07:48:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40255 Wed 11 Jan 2023 13:53:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29368 Wed 11 Apr 2018 12:48:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20595 Wed 11 Apr 2018 09:28:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55236 Wed 01 May 2024 15:39:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51273 Tue 29 Aug 2023 15:42:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55154 Tue 16 Apr 2024 15:25:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44310 40 years; 35% female, 80% receiving OAT, 62% injected drugs in the preceding month). Recent opioid overdose (preceding 12 months) was reported by 7% of participants, lifetime naloxone access by 17%, and lifetime naloxone training by 14%. Compared to people receiving OAT with no additional opioid use, recent opioid, benzodiazepine (preceding six months), and hazardous alcohol use was associated with recent opioid overdose (aOR 3.91; 95%CI: 1.68-9.10) and lifetime naloxone access (aOR 2.12; 95%CI 1.29-3.48). Among 91 people who reported recent overdose, 65% had never received take-home naloxone or naloxone training. Conclusions: Among people recently using opioids or receiving OAT, benzodiazepine and hazardous alcohol use is associated with non-fatal opioid overdose. Not all factors associated with non-fatal overdose correspond to factors associated with naloxone access. Naloxone access and training is low across all groups. Additional interventions are needed to scale up naloxone provision.]]> Tue 11 Oct 2022 16:12:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39797 Thu 23 Jun 2022 15:23:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51854 Thu 21 Sep 2023 09:40:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42382 Thu 08 Jun 2023 13:31:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38592 n = 1657) and 37% in 2017 (n = 1376) for population surveys, and 61% (n = 887) for follow-up. Cross-sectional comparisons showed no marked change in proportions reporting ever having participated in alcohol policy development (4.9% in 2014 versus 5.1% in 2017), or who objected to a licence application in the preceding year (1.0% versus 1.4%). Longitudinal comparisons also suggested little change. The most common reasons 2017 respondents gave for not participating were not knowing where to start (39%), lack of time (36%), and needing more information (32%), and this order was similar in 2014. Conclusion: Public participation in local liquor licencing is low and it has not increased substantially under the new legislation.]]> Thu 01 Sep 2022 10:15:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16463 Sat 24 Mar 2018 07:58:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19790 Sat 24 Mar 2018 07:57:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26795 Sat 24 Mar 2018 07:36:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26484 ®), and willingness and intent to receive HCV treatment among persons with a history of injection drug use participating in a liver health promotion campaign. Methods: The LiveRLife campaign involved three phases: (1) campaign resource development; (2) campaign resource testing; and (3) campaign implementation. Participants were enrolled in an observational cohort study with recruitment at four clinics - one primary health care facility, two OST clinics, and one medically supervised injecting centre - in Australia between May and October 2014. Participants received educational material, nurse clinical assessment, TE assessment, dried blood spot testing, and completed a knowledge survey. Results: Of 253 participants (mean age 43 years), 68% were male, 71% had injected in the past month, and 75% self-reported as HCV positive. Median knowledge score was 16/23. In adjusted analysis, less than daily injection (AOR 5.01; 95% CI, 2.64-9.51) and no daily injection in the past month (AOR 3.54; 95% CI, 1.80-6.94) were associated with high knowledge (≥16). TE was the most preferred method both pre- (66%) and post-TE (89%) compared to liver biopsy and blood sample. Eighty-eight percent were 'definitely willing' or 'somewhat willing' to receive HCV treatment, and 56% intended to start treatment in the next 12 months. Approximately 68% had no/mild fibrosis (F0/F1, ≥2.5 to ≤7.4. kPa), 13% moderate fibrosis (F2, ≥7.5 to ≤9.4. kPa), 10% severe fibrosis (F3, ≥9.5 to ≤12.4. kPa), and 9% had cirrhosis (F4, ≥12.5. kPa). Conclusion: Liver disease and HCV knowledge was moderate. High acceptability of TE by PWID provides strong evidence for the inclusion of TE in HCV-related care, and could help to prioritise HCV treatment for those at greatest risk of liver disease progression.]]> Sat 24 Mar 2018 07:35:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29544 Sat 24 Mar 2018 07:33:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26933 Opioid Treatment Index social functioning scale. Those classified in the highest quartile (score >6) were considered having lower social functioning. Analyses were performed using logistic regression. Results: Among 415 participants (mean age 41 years, 71% male), 24% were considered having lower social functioning, 70% had early HCV treatment intent (intention to be treated in the next 12 months), 53% were assessed by a specialist and 27% initiated treatment. Lower social functioning was independently associated with unemployment, unstable housing, recent injecting drug use and moderate to extremely severe symptoms of depression, anxiety and stress. Lower social functioning was independently associated with reduced early HCV treatment intent (aOR 0.51, 95% CI 0.30-0.84) and lower specialist assessment (aOR 0.48, 95% CI 0.29-0.79), but not HCV treatment uptake (aOR 0.76, 95% CI 0.40-1.43). Living with someone was independently associated with HCV treatment uptake (with someone and children: aOR 2.28, 95% CI 1.01-5.14; with someone and no children: aOR 2.36, 95% CI 1.30-4.31), but not early HCV treatment intent or specialist assessment. Conclusions: This study highlights the need for the development and implementation of strategies targeting people who inject drugs with lower social functioning to enhance HCV treatment intent and specialist assessment. Further, strategies to enhance social support may play a role in increasing HCV treatment uptake.]]> Sat 24 Mar 2018 07:27:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26440 Sat 24 Mar 2018 07:27:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46800 Mon 05 Dec 2022 08:29:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51937 Fri 22 Sep 2023 13:12:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53111 Fri 17 Nov 2023 11:33:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43014 Fri 09 Sep 2022 16:16:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34078 12 weeks post-treatment). Results: Among 93 people with ongoing injecting drug use or receiving OST treated for HCV genotype 2/3, 59% had recently (past month) injected drugs, 77% were receiving OST and 56% injected drugs during therapy. Overall SVR was 66% (61/93). SVR was 84% in those with undetectable HCV RNA at week 4 (12 weeks) compared to 38% in those without (24 weeks). In adjusted analysis, cirrhosis vs. no/mild fibrosis [adjusted OR (aOR) 0.33, 95% CI 0.13, 0.86] predicted reduced SVR, while response at week 4 was associated with increased SVR [aOR 8.11, 95% CI 2.73, 24.10] . Recent injecting drug use at baseline or during therapy was not associated with SVR. Conclusion: This study demonstrates that people with recent injecting drug use or OST with chronic HCV can achieve responses to interferon-based therapy similar to other populations, despite injecting drugs prior to or during therapy. Cirrhosis was predictive of reduced response to HCV therapy, while response at week 4 (despite shortened therapy) was predictive of improved response.]]> Fri 03 Dec 2021 10:35:13 AEDT ]]>